Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2002 October;93(5) > Minerva Medica 2002 October;93(5):365-70

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

REVIEWS  


Minerva Medica 2002 October;93(5):365-70

language: Italian

Testis cancer markers. Clinical use

Salesi N., Di Cocco B., Alghisi F., Calabretta F., Bossone G.


PDF  


Testis tumour is relatively rare and more frequent between 15-35 years of age. The 90% of this tumour derivates from germinal cells, the remaining cases originate from stromal cells or are secondary lesions from other neoplasms. The present clinical use of serum markers, especially alfa-fetoprotein (AFP), human chorionic gonadotrophin protein (HCG) and serum lactate deidrogenase (LDH) is examined.

top of page

Publication History

Cite this article as

Corresponding author e-mail